NH SPAC 2 (206640) - Total Liabilities

Latest as of September 2025: ₩37.56 Billion KRW ≈ $25.45 Million USD

Based on the latest financial reports, NH SPAC 2 (206640) has total liabilities worth ₩37.56 Billion KRW (≈ $25.45 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of NH SPAC 2 to assess how effectively this company generates cash.

NH SPAC 2 - Total Liabilities Trend (2015–2024)

This chart illustrates how NH SPAC 2's total liabilities have evolved over time, based on quarterly financial data. Check 206640 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

NH SPAC 2 Competitors by Total Liabilities

The table below lists competitors of NH SPAC 2 ranked by their total liabilities.

Company Country Total Liabilities
New England Realty Associates LP
NYSE MKT:NEN
USA $563.89 Million
Mpact Limited
JSE:MPT
South Africa ZAC6.42 Billion
Chia Chang Co Ltd
TW:4942
Taiwan NT$2.71 Billion
Bank Ganesha Tbk PT
JK:BGTG
Indonesia Rp6.59 Trillion
The Pinkfong Company
KQ:403850
Korea ₩19.06 Billion
Arman Financial Services Limited
NSE:ARMANFIN
India Rs12.81 Billion
Wallix Group SA
PA:ALLIX
France €43.49 Million
Equity Commonwealth
NYSE:EQC
USA $51.16 Million

Liability Composition Analysis (2015–2024)

This chart breaks down NH SPAC 2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NH SPAC 2 (206640) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 5.05 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.17 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.14 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how NH SPAC 2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for NH SPAC 2 (2015–2024)

The table below shows the annual total liabilities of NH SPAC 2 from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩31.62 Billion
≈ $21.43 Million
+3.73%
2023-12-31 ₩30.49 Billion
≈ $20.66 Million
-5.03%
2022-12-31 ₩32.10 Billion
≈ $21.75 Million
-22.00%
2021-12-31 ₩41.15 Billion
≈ $27.89 Million
-5.65%
2020-12-31 ₩43.62 Billion
≈ $29.56 Million
+57.37%
2019-12-31 ₩27.71 Billion
≈ $18.78 Million
-27.28%
2018-12-31 ₩38.11 Billion
≈ $25.83 Million
-5.42%
2017-12-31 ₩40.29 Billion
≈ $27.31 Million
+157.90%
2016-12-31 ₩15.62 Billion
≈ $10.59 Million
+28.06%
2015-12-31 ₩12.20 Billion
≈ $8.27 Million
--

About NH SPAC 2

KQ:206640 Korea Medical Devices
Market Cap
$169.86 Million
₩250.65 Billion KRW
Market Cap Rank
#17145 Global
#772 in Korea
Share Price
₩11690.00
Change (1 day)
-0.76%
52-Week Range
₩10510.00 - ₩18040.00
All Time High
₩36222.75
About

Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testi… Read more